Compare Incyte Corporation (INCY) vs Global X Robo Global Robotics & Automation ETF (ROBO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Global X Robo Global Robotics & Automation ETF — how do they compare? Incyte Corporation trades at $117.94 (market cap $23.11B), while Global X Robo Global Robotics & Automation ETF trades at $79.44. The key difference: Incyte Corporation is trading nearer its 52-week high, Global X Robo Global Robotics & Automation ETF nearer its low. Which is the better fit depends on your goals.
| INCY | ROBO | |
|---|---|---|
Market Cap | $23.11B | — |
Sector | Health | Sector/Thematic |
52-Week High | $118.52 | $90.34 |
52-Week Low | $67.38 | $61.34 |
Enterprise Value | $19.13B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INCY trades at $115.66, down 1.36% on the day, with a bullish technical signal from moving averages and strong fundamental performance including a 25.02% net income margin for 2025. Recent positive news includes regulatory approvals for Opzelura in Europe and the acquisition of Vega Therapeutics, expanding its hematology portfolio. Revenue grew to $5.14 billion in 2025, with earnings beating expectations in two of the last three quarters.
The outlook remains positive given robust profitability, pipeline advancements, and a majority analyst buy rating, though risks include competitive pressures and reliance on key drug performance. The stock's current price is slightly above the consensus target of $112.78, suggesting near-term consolidation potential amid longer-term growth catalysts.
ROBO Global Robotics and Automation Index ETF trades at $77.31, down 0.74% with a bearish technical signal from moving averages. The ETF provides diversified exposure to robotics and AI themes with 79 holdings across machinery and electronic equipment sectors. Recent index rebalancing has shifted weight toward AI infrastructure and physical automation themes, reflecting evolving technology trends.
The ETF offers growth exposure to the expanding physical AI ecosystem but faces cyclical risks from industrial markets. While thematic positioning remains relevant, valuation concerns exist with a 24.9x P/E ratio. Key catalysts include AI infrastructure development and reshoring trends, though competition and market volatility present ongoing challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Global X Robo Global Robotics & Automation ETF
ROBO is a thematic ETF that tracks the global robotics and automation industry. It provides diversified exposure to companies leading in industrial robotics, 3D printing, and surgical systems, with holdings like Intuitive Surgical and Zebra Technologies.
Read more on ROBO →
